The Suppression of the Synthesis of a Nuclear Protein in Cells Blocked in G 2 Phase: Identification of NP-170 as Topoisomerase II

1992 ◽  
Vol 132 (2) ◽  
pp. 162 ◽  
Author(s):  
P. C. Goswami ◽  
M. Hill ◽  
R. Higashikubo ◽  
W. D. Wright ◽  
J. L. Roti Roti
2002 ◽  
Vol 35 (6) ◽  
pp. 435-440 ◽  
Author(s):  
Yoshihiro Yoneda ◽  
Ai Kametaka ◽  
Toshihiro Sekimoto

2007 ◽  
Vol 54 (2) ◽  
pp. 297-306 ◽  
Author(s):  
Marcin Koba ◽  
Jerzy Konopa

Triazoloacridinones (TA) are a new group of potent antitumor compounds, from which the most active derivative, C-1305, has been selected for extended preclinical trials. This study investigated the mechanism of TA binding to DNA. Initially, for selected six TA derivatives differing in chemical structures as well as cytotoxicity and antitumor activity, the capability of noncovalent DNA binding was analyzed. We showed that all triazoloacridinones studied stabilized the DNA duplex at a low-concentration buffer but not at a salt concentration corresponding to that in cells. DNA viscometric studies suggested that intercalation to DNA did not play a major role in the mechanism of the cytotoxic action of TA. Studies involving cultured cells revealed that triazoloacridinone C-1305 after previous metabolic activation induced the formation of interstrand crosslinks in DNA of some tumor and fibroblast cells in a dose dependent manner. However, the detection of crosslink formation was possible only when the activity of topoisomerase II in cells was lowered. Furthermore, it was impossible to validate the relevance of the ability to crosslink DNA to biological activity of TA derivatives.


2008 ◽  
Vol 82 (12) ◽  
pp. 5922-5932 ◽  
Author(s):  
Y.-C. James Lin ◽  
Jianhong Li ◽  
Chad R. Irwin ◽  
Heather Jenkins ◽  
Luke DeLange ◽  
...  

ABSTRACT Vaccinia virus replication is inhibited by etoposide and mitoxantrone even though poxviruses do not encode the type II topoisomerases that are the specific targets of these drugs. Furthermore, one can isolate drug-resistant virus carrying mutations in the viral DNA ligase and yet the ligase is not known to exhibit sensitivity to these drugs. A yeast two-hybrid screen was used to search for proteins binding to vaccinia ligase, and one of the nine proteins identified comprised a portion (residue 901 to end) of human topoisomerase IIβ. One can prevent the interaction by introducing a C11-to-Y substitution mutation into the N terminus of the ligase bait protein, which is one of the mutations conferring etoposide and mitoxantrone resistance. Coimmunoprecipitation methods showed that the native ligase and a Flag-tagged recombinant protein form complexes with human topoisomerase IIα/β in infected cells and that this interaction can also be disrupted by mutations in the A50R (ligase) gene. Immunofluorescence microscopy showed that both topoisomerase IIα and IIβ antigens are recruited to cytoplasmic sites of virus replication and that less topoisomerase was recruited to these sites in cells infected with mutant virus than in cells infected with wild-type virus. Immunoelectron microscopy confirmed the presence of topoisomerases IIα/β in virosomes, but the enzyme could not be detected in mature virus particles. We propose that the genetics of etoposide and mitoxantrone resistance can be explained by vaccinia ligase binding to cellular topoisomerase II and recruiting this nuclear enzyme to sites of virus biogenesis. Although other nuclear DNA binding proteins have been detected in virosomes, this appears to be the first demonstration of an enzyme being selectively recruited to sites of poxvirus DNA synthesis and assembly.


2009 ◽  
Vol 315 (14) ◽  
pp. 2373-2385 ◽  
Author(s):  
Albert Busch ◽  
Tilman Kiel ◽  
Wolfgang-M. Heupel ◽  
Manfred Wehnert ◽  
Stefan Hübner

2005 ◽  
Vol 65 (10) ◽  
pp. 4067-4077 ◽  
Author(s):  
Wan Jiao ◽  
Huei-Min Lin ◽  
Jamie Timmons ◽  
Akhilesh K. Nagaich ◽  
Shu-Wing Ng ◽  
...  

2018 ◽  
Vol 19 (7) ◽  
pp. 2056 ◽  
Author(s):  
Ka Lee ◽  
Rebecca Swan ◽  
Zbyslaw Sondka ◽  
Kay Padget ◽  
Ian Cowell ◽  
...  

DNA topoisomerase II (TOP2) activity involves a normally transient double-strand break intermediate in which the enzyme is coupled to DNA via a 5′-phosphotyrosyl bond. However, etoposide and other topoisomerase drugs poison the enzyme by stabilising this enzyme-bridged break, resulting in the accumulation of TOP2-DNA covalent complexes with cytotoxic consequences. The phosphotyrosyl diesterase TDP2 appears to be required for efficient repair of this unusual type of DNA damage and can remove 5′-tyrosine adducts from a double-stranded oligonucleotide substrate. Here, we adapt the trapped in agarose DNA immunostaining (TARDIS) assay to investigate the role of TDP2 in the removal of TOP2-DNA complexes in vitro and in cells. We report that TDP2 alone does not remove TOP2-DNA complexes from genomic DNA in vitro and that depletion of TDP2 in cells does not slow the removal of TOP2-DNA complexes. Thus, if TDP2 is involved in repairing TOP2 adducts, there must be one or more prior steps in which the protein-DNA complex is processed before TDP2 removes the remaining 5′ tyrosine DNA adducts. While this is partly achieved through the degradation of TOP2 adducts by the proteasome, a proteasome-independent mechanism has also been described involving the SUMOylation of TOP2 by the ZATT E3 SUMO ligase. The TARDIS assay was also adapted to measure the effect of TDP2 knockdown on levels of SUMOylated TOP2-DNA complexes, which together with levels of double strand breaks were unaffected in K562 cells following etoposide exposure and proteasomal inhibition.


Sign in / Sign up

Export Citation Format

Share Document